Protein recombinant vaccine NVX-CoV2373 confers protection during Omicron dominant period in Italy

FHS
October 8, 2023
10:29 pm

The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.

Mydecine Announces Update Regarding the Special Access Program | Psychedelic Invest

Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly

November 29, 2023

Sino Biological concludes SignalChem acquisition for $48m

Share this article The merger is expected to deliver a wider range of products and services to the life sciences community. Credit: Gorodenkoff/Shutterstock.com. Sino Biological

April 29, 2024

Multi-omics approach identifies potential drug combinations for AML treatment

Acute myeloid leukaemia (AML) is mainly characterized by an increase in the number of myeloid cells in the bone marrow and a decrease in mature

January 24, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.